India CRO market seen doubling to $12 billion by 2035

India’s contract research organization market is forecast to grow from $6.74 billion in 2025 to $12.0 billion by 2035, driven by pharma R&D, rising clinical trial activity and supportive policy shifts. The outlook points to stronger demand for outsourced research as India deepens its role in global drug development.

Why it matters: - India’s CRO market is expected to nearly double over the next decade, signaling deeper outsourcing demand across drug development, clinical trials and regulatory work. - The growth path reflects India’s expanding role in global pharmaceutical research as sponsors look for lower-cost, faster and larger-scale trial execution. - The market’s rise could also strengthen India’s position as a destination for biotechnology, genomics and specialized research services.

What happened: - Market Research Future projected the India Contract Research Organization market will reach $12.0 billion by 2035, up from $6.74 billion in 2025. - The report put the market at $6.32 billion in 2024. - The forecast implies a 6.0% compound annual growth rate from 2025 through 2035. - The report said the expansion is being driven by pharmaceutical R&D growth, rising clinical trial activity and a more supportive policy environment. - The release included a free sample request and a detailed report.

The details: - India’s pharmaceutical industry is projected to reach $130 billion by 2030, according to the report. - India accounts for about 3.6% of global pharmaceutical production. - More than 1,000 clinical trials were registered in India in 2025. - Clinical trials were the largest application segment in 2024, with a 58% share. - Pharmaceutical services were the largest service type in 2024, with a 63% share. - Pharmaceutical companies were the dominant end user in 2024, with a 67% share. - Biotechnology services were the fastest-growing service type segment. - Regulatory affairs were the fastest-growing application segment. - Biotechnology firms were the fastest-growing end-user segment. - The report said India’s large and diverse patient pool supports faster recruitment for trials. - Cost-effective services remain a key draw for sponsors choosing India. - A skilled scientific workforce and evolving regulatory framework also support CRO activity. - Government measures cited in the report include the National Biotechnology Development Strategy and tax incentives for research. - The World Health Organization says noncommunicable diseases account for about 74% of global deaths, which is fueling demand for new therapies and clinical research.

Between the lines: - The report suggests India is moving beyond being only a low-cost research location. - Technology-enabled services such as decentralized trials, AI-driven analytics and digital data platforms are becoming competitive differentiators. - The market appears moderately fragmented, but the report points to consolidation as firms broaden capabilities and geography. - The emphasis on clinical trials and regulatory expertise signals where the highest-value outsourcing opportunities are likely to sit. - Large multinational CROs are using partnerships and advanced trial tools to deepen their presence in India.

What’s next: - The report expects decentralized and hybrid trial models to expand as sponsors look for remote monitoring, direct-to-patient delivery and virtual site management. - AI and machine learning adoption is likely to grow in patient recruitment, protocol optimization and trial monitoring. - Partnerships with biotech firms are expected to increase as genomics, biologics and personalized medicine gain ground. - The report sees India evolving into a fuller innovation hub for outsourced research by 2035. - Major CROs named in the release include IQVIA, Syneos Health, Syngene International, PAREXEL International, Covance, Charles River Laboratories, Siro Clinpharm and Clininvent Research Pvt. Ltd. - The release also pointed to ongoing expansion and digital investment by several of those firms, including new facilities, platforms and partnerships in 2025 and 2026.

The bottom line: - India’s CRO market is on track for steady, policy-backed growth, with clinical trials, biotech services and digital research tools shaping the next decade.